LONDON, Oct 5 (Reuters) - Swiss drugmaker Roche (ROG.VX), battered by recent setbacks for key medicines, is banking on a batch of upcoming clinical trial data to restore belief in its pipeline.
LONDON, Oct 5 (Reuters) - Swiss drugmaker Roche (ROG.VX), battered by recent setbacks for key medicines, is banking on a batch of upcoming clinical trial data to restore belief in its pipeline.